ovarian carcinoma (Cancer)
Information
- Disease name
- ovarian carcinoma
- Disease ID
- DOID:4001
- Description
- "An ovarian cancer that has_material_basis_in epithelial tissue and is located_in the ovary." [url:https\://www.cancer.gov/types/ovarian]
Disease area statistics
[No Data.]
Chromosome band
[No Data.]
Annotation
| Genes | Mutation | Description | Source | Links |
|---|
| NCT ID | Status | Phase | Summary | Start date | Completion date |
|---|---|---|---|---|---|
| NCT02194387 | Active, not recruiting | N/A | Energy Balance Interventions in Increasing Physical Activity in Breast Cancer Gene Positive Patients, Lynch Syndrome-Positive Patients, CLL Survivors or High-Risk Family Members | September 17, 2014 | September 30, 2025 |
| NCT04917744 | Active, not recruiting | Metabolite Levels in Ovarian Cancer Patients Receiving Maintenance PARP Inhibitors | April 1, 2021 | March 19, 2025 | |
| NCT03839524 | Active, not recruiting | Phase 1 | A Trial Evaluating TG4050 in Ovarian Carcinoma. | December 9, 2019 | December 2025 |
| NCT05194735 | Active, not recruiting | Phase 1/Phase 2 | Phase I/II Study of Autologous T Cells to Express T-Cell Receptors (TCRs) in Subjects With Solid Tumors | April 4, 2022 | November 30, 2024 |
| NCT01696994 | Active, not recruiting | N/A | Screening for Ovarian Cancer in Older Patients (PLCO Screening Trial) | November 16, 1993 | March 11, 2025 |
| NCT02345265 | Active, not recruiting | Phase 2 | Testing the Combination of the Study Drugs Cediranib and Olaparib in Recurrent Ovarian Cancer | May 23, 2016 | August 9, 2024 |
| NCT01366144 | Active, not recruiting | Phase 1 | Veliparib, Paclitaxel, and Carboplatin in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery and Liver or Kidney Dysfunction | June 20, 2011 | March 5, 2025 |
| NCT02419495 | Active, not recruiting | Phase 1 | Phase IB Study to Evaluate the Safety of Selinexor (KPT-330) in Combination With Multiple Standard Chemotherapy or Immunotherapy Agents in Patients With Advanced Malignancies | June 26, 2015 | December 31, 2024 |
| NCT02465060 | Active, not recruiting | Phase 2 | Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial) | August 17, 2015 | December 31, 2025 |
| NCT02487693 | Active, not recruiting | Phase 2 | Radiofrquency Ablation Combined With Cytokine-induced Killer Cells for the Patients With Ovarian Carcinoma | July 2015 | June 2040 |
| NCT03748186 | Active, not recruiting | Phase 1 | Study of STRO-002, an Anti-Folate Receptor Alpha (FolRα) Antibody Drug Conjugate in Ovarian & Endometrial Cancers | February 1, 2019 | November 2024 |
| NCT01907789 | Active, not recruiting | N/A | Prophylactic Salpingectomy With Delayed Oophorectomy | August 26, 2013 | December 31, 2030 |
| NCT04310826 | Active, not recruiting | N/A | Dietary Magnesium in Preventing Low Blood Magnesium Levels in Patients With Ovarian Cancer Receiving Carboplatin Chemotherapy | April 23, 2019 | April 1, 2024 |
| NCT02584478 | Active, not recruiting | Phase 3 | Phase 1/2a/3 Evaluation of Adding AL3818 to Standard Platinum-Based Chemotherapy in Subjects With Recurrent or Metastatic Endometrial, Ovarian, Fallopian, Primary Peritoneal or Cervical Carcinoma (AL3818-US-002) | December 2015 | December 2024 |
| NCT05446870 | Active, not recruiting | Phase 2 | Pembrolizumab With Chemotherapy and MK-4830 for Treating Participants With Ovarian Cancer (MK-4830-002) | July 25, 2022 | December 26, 2024 |
| NCT04257045 | Active, not recruiting | Factors Influencing Cascade Testing Among Women With Hereditary Gynecological Cancers and Their Relatives | August 21, 2019 | April 30, 2024 | |
| NCT03965481 | Active, not recruiting | N/A | PET/MR Versus CECT Scans in Imaging Patients With Ovarian Cancer or Highly Suspected Ovarian Cancer | May 12, 2018 | April 30, 2025 |
| NCT02124421 | Active, not recruiting | Phase 2 | HOT: HIPEC in Ovarian Cancer as Initial Treatment | April 2014 | April 2028 |
| NCT05200364 | Active, not recruiting | Phase 1 | A Study of STRO-002, an Anti-Folate Receptor Alpha Antibody Drug Conjugate, in Combination With Bevacizumab in Epithelial Ovarian Cancer | March 22, 2022 | January 2026 |
| NCT04905082 | Active, not recruiting | N/A | HOPE-Genomics Intervention for the Improvement of Cancer Patient Knowledge of Genomics | December 30, 2021 | June 30, 2024 |
| NCT04902144 | Completed | N/A | Clinical Outcomes for Offering Genetic Testing in a Tiered Approach | August 3, 2020 | December 31, 2021 |
| NCT01481701 | Completed | Phase 2 | A Trial Evaluating Efficacy and Safety of Oxaliplatin With 5-Fluorouracil in Patients With Recurrent Ovarian Carcinoma | October 2008 | May 2014 |
| NCT01519869 | Completed | Phase 2 | Trial of Chemotherapy in Ovarian, Fallopian Tube and Peritoneal Carcinoma | March 2012 | October 11, 2019 |
| NCT01657747 | Completed | N/A | Whole-body Diffusion MRI for Staging, Response Prediction and Detecting Tumor Recurrence in Patients With Ovarian Cancer | November 2011 | March 2015 |
| NCT01689714 | Completed | Phase 2 | Safety and Efficacy of Folatescan (Technetium TC 99M EC20) in Patients With Suspected Ovarian Carcinoma or Recurrent Endometrial Carcinoma | August 2003 | August 2005 |
| NCT01709487 | Completed | Phase 1/Phase 2 | Feasibility Study of HIPEC for Patients With Stage III or Only Pleural Stage IV Ovarian Carcinoma in First Line Therapy | May 2010 | October 2015 |
| NCT02025985 | Completed | Phase 2 | Study of KPT-330 (Selinexor) in Female Patients With Advanced Gynaecologic Malignancies | April 9, 2014 | March 29, 2017 |
| NCT02159989 | Completed | Phase 1 | Sapanisertib and Ziv-Aflibercept in Treating Patients With Recurrent Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery | June 18, 2014 | January 29, 2024 |
| NCT02166905 | Completed | Phase 1/Phase 2 | DEC-205/NY-ESO-1 Fusion Protein CDX-1401, Poly ICLC, and IDO1 Inhibitor INCB024360 in Treating Patients With Ovarian, Fallopian Tube, or Primary Peritoneal Cancer in Remission | October 10, 2014 | August 20, 2020 |
| NCT03857087 | Completed | 68Ga-PSMA PET in Diagnosing Metastasis in Patients With Ovarian Cancer | April 2, 2018 | June 30, 2022 | |
| NCT02297958 | Completed | Impact of Fas/FasL in Chemotherapy Response in Epithelial Ovarian Carcinoma | January 15, 2015 | July 27, 2019 | |
| NCT02315469 | Completed | Comprehensive Patient Questionnaires in Predicting Complications in Older Patients With Gynecologic Cancer Undergoing Surgery | February 10, 2015 | February 9, 2019 | |
| NCT03756818 | Completed | Phase 1 | TAK-659 and Paclitaxel in Treating Patients With Advanced Solid Tumors | March 5, 2019 | February 23, 2023 |
| NCT02578888 | Completed | N/A | Palliative Care in Improving Quality of Life in Patients With High Risk Primary or Recurrent Gynecologic Malignancies | April 2015 | April 2019 |
| NCT02584465 | Completed | Phase 2 | REGorafenib vsTamoxifen in Patients With Platinum-sensitive OVARian Carcinoma and Isolated Biological Progression | August 28, 2015 | September 19, 2021 |
| NCT02595281 | Completed | N/A | HE4 as a Relapse Biomarker in Ovarian Cancers | April 1, 2016 | July 18, 2022 |
| NCT03562533 | Completed | Real-World Effectiveness of PLD in Platinum- Sensitive Recurrent Ovarian Cancer | May 17, 2018 | December 17, 2018 | |
| NCT03517488 | Completed | Phase 1 | A Study of XmAb®20717 in Subjects With Selected Advanced Solid Tumors | July 10, 2018 | September 6, 2022 |
| NCT03027479 | Completed | N/A | Skeletal Muscle Energy Metabolism in Women With Weight Loss and Ovarian and/or Endometrial Cancer With Weight Loss | March 1, 2017 | July 16, 2019 |
| NCT03379376 | Completed | N/A | EHealth Mindful Movement and Breathing in Improving Outcomes in Participants Undergoing Gynecologic Surgery | April 5, 2018 | November 2, 2018 |
| NCT03372720 | Completed | N/A | Fractional CO2 Laser Therapy in Minimizing Genitourinary Syndrome of Menopause in Gynecological Cancer Survivors | May 11, 2018 | April 12, 2022 |
| NCT03085225 | Completed | Phase 1 | Trabectedin Combined With Durvalumab in Patients With Advanced Pretreated Soft-tissue Sarcomas and Ovarian Carcinomas. | May 5, 2017 | January 4, 2022 |
| NCT03180294 | Completed | Phase 2 | Bupropion Hydrochloride in Improving Sexual Desire in Women With Breast or Gynecologic Cancer | May 31, 2017 | February 22, 2021 |
| NCT00181701 | Completed | Phase 2 | Intraperitoneal Paclitaxel and Carboplatin in the Treatment of Women With Carcinoma of Mullerian Origin | October 2004 | May 2006 |
| NCT00183794 | Completed | Phase 2 | Clinical Trial of Docetaxel in Combination With Gemcitabine in Platinum-Resistant Ovarian Cancer and Primary Peritoneal Carcinoma | November 2002 | May 2010 |
| NCT00214058 | Completed | Phase 2 | Weekly Carboplatin/Docetaxel for Recurrent Ovarian/Peritoneal Cancer | August 2002 | February 2006 |
| NCT00305695 | Completed | Phase 2 | Zoledronate or Observation in Maintaining Bone Mineral Density in Patients Who Are Undergoing Surgery to Remove Both Ovaries | November 28, 2005 | |
| NCT00445887 | Completed | Phase 2 | Levonorgestrel in Preventing Ovarian Cancer in Patients at High Risk for Ovarian Cancer | March 10, 2008 | |
| NCT00474669 | Completed | Phase 1 | A Phase I Study of Intraperitoneal Hyperthermic Docetaxel | June 2007 | December 2009 |
| NCT00623831 | Completed | Phase 1 | A Phase 1 Study of Mixed Bacteria Vaccine (MBV) in Patients With Tumors Expressing NY-ESO-1 Antigen | May 2007 | May 2013 |
| NCT05001347 | Completed | Phase 2 | A Clinical Study of TJ004309 With Atezolizumab (TECENTRIQ®) in Patients With Ovarian Cancer and Selected Solid Tumors | November 2, 2021 | February 8, 2023 |
| NCT00679783 | Completed | Phase 2 | Phase II Study of AZD2281 in Patients With Known BRCA Mutation Status or Recurrent High Grade Ovarian Cancer or Patients With Known BRCA Mutation Status/ Triple Neg Breast Cancer | July 8, 2008 | July 20, 2022 |
| NCT00721890 | Completed | Phase 2 | Green Tea Intake for the Maintenance of Complete Remission in Women With Advanced Ovarian Carcinoma | June 2008 | June 2013 |
| NCT00756847 | Completed | Phase 1 | Safety Study of XL147 (SAR245408), in Combination With Paclitaxel and Carboplatin in Adults With Solid Tumors | September 2008 | October 2012 |
| NCT00853307 | Completed | Phase 2 | MLN8237 for Treatment of Participants With Ovarian, Fallopian Tube, or Peritoneal Carcinoma | March 23, 2009 | January 27, 2011 |
| NCT00862355 | Completed | Phase 1 | Bioequivalence Study of SPARC147609 in Patients With Ovarian Cancer | March 2010 | January 2011 |
| NCT00868192 | Completed | Phase 2 | Trial of Pemetrexed and Bevacizumab for Recurrent Ovarian Primary Peritoneal Carcinoma | May 2008 | December 2012 |
| NCT00892736 | Completed | Phase 1 | Veliparib in Treating Patients With Malignant Solid Tumors That Do Not Respond to Previous Therapy | April 20, 2009 | May 19, 2017 |
| NCT00989651 | Completed | Phase 1 | Carboplatin, Paclitaxel, Bevacizumab, and Veliparib in Treating Patients With Newly Diagnosed Stage II-IV Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer | October 28, 2009 | April 10, 2020 |
| NCT01091428 | Completed | Phase 2 | Alisertib (MLN8237) in Participants With Ovarian, Fallopian Tube or Peritoneal Cancer Preceded by Phase 1 Study of MLN8237 Plus Paclitaxel Treatment of Ovary or Breast Cancer | April 16, 2010 | July 19, 2017 |
| NCT01295489 | Completed | Biomarkers in Patients With Previously Untreated Invasive Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer | March 2011 | ||
| NCT06422455 | Not yet recruiting | N/A | Access to Genetic Testing in Underserved Patients With Cancer | July 1, 2024 | July 1, 2027 |
| NCT01445275 | Not yet recruiting | Cost of Cancer Risk Management in Women at Elevated Genetic Risk for Ovarian Cancer Who Participated on GOG-0199 | January 2100 | ||
| NCT05591560 | Not yet recruiting | N/A | Itraconazole in Advanced Ovarian Cancer | October 2022 | October 2024 |
| NCT05714306 | Not yet recruiting | Phase 1/Phase 2 | PEP-DC and OC-DC Vaccine in High Grade Serous Ovarian Carcinoma | June 2023 | March 2030 |
| NCT05949424 | Not yet recruiting | Phase 4 | OPTI - DOSE: Optimal Dosing of Oral Anticancer Drugs in Older Adults | May 2024 | March 2025 |
| NCT06321484 | Not yet recruiting | Phase 1 | Intraperitoneal Cytokine-Induced Memory Like (CIML) Natural Killer (NK) Cells in Recurrent Ovarian Cancer | May 2024 | October 31, 2031 |
| NCT06393543 | Not yet recruiting | International Registration of Isolated STIC: to Report and Investigate the Risk of Serous Peritoneal Carcinomatosis | June 2024 | June 2034 | |
| NCT04147494 | Recruiting | Early Phase 1 | Experimental PET Imaging Scans Before Cancer Surgery to Study the Amount of PET Tracer Accumulated in Normal and Cancer Tissues | November 5, 2019 | October 17, 2031 |
| NCT04251052 | Recruiting | N/A | A Study to Compare Two Surgical Procedures in Individuals With BRCA1 Mutations to Assess Reduced Risk of Ovarian Cancer | September 1, 2020 | June 23, 2037 |
| NCT05927818 | Recruiting | N/A | Sentinel Lymph Node Biopsy in Early-Stage Ovarian Cancer | April 15, 2023 | January 15, 2026 |
| NCT05773859 | Recruiting | Phase 1/Phase 2 | NEOadjuvant Dendritic Cell Vaccination for Ovarian Cancer | March 17, 2023 | October 2024 |
| NCT05415527 | Recruiting | N/A | Evaluation of Pretreatment Sarcopenia in Patients With Inoperable High-grade Ovarian Carcinoma as Part of Optimised Management | June 11, 2022 | January 2026 |
| NCT05429970 | Recruiting | N/A | A Study Comparing Perioperative Stress Reduction vs. Standard of Care in Ovarian Cancer (PRESERVE) | June 17, 2022 | June 17, 2025 |
| NCT06420973 | Recruiting | Phase 2 | RC48 Treatment for Platinum Sensitive Recurrent Ovarian Cancer With HER2 Expression | May 16, 2024 | September 17, 2027 |
| NCT05494580 | Recruiting | Phase 1/Phase 2 | Pamiparib Plus Surufatinib in Patients With Platinum-resistant Ovarian Cancer | September 22, 2022 | August 10, 2025 |
| NCT05498597 | Recruiting | Phase 1 | AMT-151 in Patients With Selected Advanced Solid Tumours | January 25, 2023 | October 30, 2024 |
| NCT05576519 | Recruiting | Immunohistochemical Expression of Epithelial Cell Adhesion Molecule (EpCAM) in Epithelial Ovarian Carcinoma | June 1, 2017 | December 30, 2022 | |
| NCT06299163 | Recruiting | Phase 1 | NM32-2668 in Adult Patients With Selected Advanced Solid Tumors | May 1, 2024 | December 31, 2027 |
| NCT05610501 | Recruiting | Ultrasound-guided Tru-Cut Biopsy in Pelvic Masses. | May 1, 2021 | April 30, 2024 | |
| NCT02073500 | Recruiting | Peritoneal Surface Malignancies - Characterization, Models and Treatment Strategies | September 2009 | August 2027 | |
| NCT03296826 | Recruiting | Prospective Cohort Study of Germline Variant Carriers With BRCA1 or BRCA2 | November 8, 2017 | March 31, 2032 | |
| NCT03842982 | Recruiting | Phase 3 | Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Ovarian Cancer (CHIPPI) | April 1, 2019 | August 1, 2028 |
| NCT04562623 | Recruiting | Prospective Study of Immune Alterations in Operable Breast and Ovarian Carcinoma | July 1, 2021 | July 2031 | |
| NCT06285097 | Recruiting | Phase 1 | A Study of PF-07820435 as a Single Agent and in Combination in Participants With Advanced Solid Tumors | February 8, 2024 | April 29, 2028 |
| NCT03150121 | Recruiting | N/A | Biomarkers for Early Detection of Ovarian Cancer Using Uterine Lavage | June 29, 2014 | December 31, 2024 |
| NCT04686682 | Recruiting | Phase 1/Phase 2 | A First-in-Human, JAB-8263 in Adult Patients With Advanced Tumors | May 7, 2021 | September 2024 |
| NCT04851119 | Recruiting | Phase 1/Phase 2 | Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors | November 8, 2021 | June 30, 2028 |
| NCT04878094 | Recruiting | Phase 3 | A Study of Intra-operative Imaging in Women With Ovarian Cancer | May 3, 2021 | May 3, 2025 |
| NCT03604315 | Recruiting | Phase 1 | Serial Imaging of the Novel Radiotracer [^18F] FLuorthanatrace ([^18F] FTT) by PET/CTF | December 18, 2018 | June 30, 2027 |
| NCT06264921 | Recruiting | Phase 1 | A Study With NKT3447 for Adults With Advanced/Metastatic Solid Tumors | February 23, 2024 | May 2025 |
| NCT06216561 | Recruiting | Phase 1 | Intraperitoneal LSTA1 in CRS-HIPEC | November 30, 2023 | December 2029 |
| NCT04981119 | Recruiting | Solid Tumor Analysis for HLA Loss of Heterozygosity (LOH) and Apheresis for CAR T- Cell Manufacturing | October 29, 2021 | December 2026 | |
| NCT04997096 | Recruiting | N/A | Exercise as a Preventive Agent to Combat Immobility in Patients With Ovarian or Endometrial Cancers Receiving Chemotherapy | April 2, 2022 | April 30, 2025 |
| NCT05001282 | Recruiting | Phase 1/Phase 2 | A Study to Evaluate ELU001 in Patients With Solid Tumors That Overexpress Folate Receptor Alpha (FRα) | September 13, 2021 | June 15, 2025 |
| NCT06172478 | Recruiting | Phase 2 | A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors | February 26, 2024 | April 30, 2026 |
| NCT06290193 | Recruiting | Phase 2 | Study of Acute Normovolemic Hemodilution (ANH) in People With Ovarian Cancer Who Are Having Primary Cytoreductive Surgery | February 23, 2024 | February 23, 2029 |
| NCT06028932 | Recruiting | Phase 2 | A Study of Sacituzumab Govitecan (IMMU-132) in Platinum-resistant Ovarian Cancer Patients | January 8, 2024 | November 1, 2027 |
| NCT00488878 | Recruiting | Data Collection for Patients With Low Grade Ovarian or Peritoneal Tumors | May 19, 2006 | May 1, 2035 | |
| NCT01175772 | Terminated | Phase 2 | Maintenance Treatment for Ovarian Carcinoma in Remission by an Antiangiogenic Treatment Strategy | August 2010 | April 2013 |
| NCT02708511 | Terminated | Phase 1 | Copper Cu 64-DOTA-B-Fab PET/CT in Imaging Patients With Ovarian and Breast Cancer | August 2016 | October 11, 2017 |
| NCT02412124 | Terminated | N/A | Peer-to-Peer Support Program in Improving Quality of Life Outcomes in Patients With Gynecologic Cancer and Their Caregivers | July 2015 | April 2018 |
| NCT02218502 | Terminated | N/A | Study Into a New Diagnostic Tool (Simple Ultrasound-based Rules) in Patients With Adnexal Masses | September 2014 | October 1, 2015 |
| NCT03957096 | Terminated | Phase 1 | A Safety Study of SGN-CD47M in Patients With Solid Tumors | July 17, 2019 | September 14, 2020 |
| NCT01936974 | Terminated | Phase 2 | (PGA) for Platinum-resistant/Refractory, Paclitaxel-Pretreated Recurrent Ovarian and Peritoneal Carcinoma | September 2013 | August 2015 |
| NCT04442126 | Terminated | Phase 1/Phase 2 | A Study of NM21-1480 in Adult Patients With Advanced Solid Tumors | August 19, 2020 | February 6, 2024 |
| NCT04628780 | Terminated | Phase 1 | Study to Test the Safety and Tolerability of PF-07209960 in Advanced or Metastatic Solid Tumors | December 16, 2020 | May 26, 2023 |
| NCT01312376 | Terminated | Phase 1 | Autologous T-Cells Combined With Autologous OC-DC Vaccine in Ovarian Cancer | March 2011 | January 2019 |
| NCT05012397 | Terminated | Phase 2 | Milademetan in Advanced/Metastatic Solid Tumors | November 1, 2021 | October 15, 2023 |
| NCT00312650 | Terminated | Phase 2 | Doxil and Gemcitabine in Recurrent Ovarian Cancer | April 2006 | May 2006 |
| NCT05261490 | Terminated | Phase 1/Phase 2 | Study of Maplirpacept (PF-07901801) in Combination With PLD in Patients With Platinum-Resistant Ovarian Cancer | August 1, 2022 | February 15, 2024 |
| NCT00047632 | Terminated | Phase 3 | Safety and Efficacy of Interferon Gamma-1b Plus Chemotherapy for Ovarian and Peritoneal Cancer | October 2001 | February 2006 |
| NCT03029585 | Terminated | Phase 2 | Phase II Study of Intraperitoneal NanoPac® in Patients With Ovarian Cancer | April 19, 2017 | November 4, 2019 |
| NCT03382574 | Terminated | Early Phase 1 | Pilot Study of Denosumab in BRCA1/2 Mutation Carriers Scheduled for Risk-Reducing Salpingo-Oophorectomy | March 14, 2019 | October 22, 2021 |
| NCT02244502 | Unknown status | Phase 1/Phase 2 | Safety, Feasibility and Effect of TTFields (200 kHz) Concomitant With Weekly Paclitaxel in Recurrent Ovarian Carcinoma (INNOVATE) | September 2014 | December 2016 |
| NCT03302884 | Unknown status | N/A | Circulating Tumor DNA as an Early Marker of Recurrence and Treatment Efficacy in Ovarian Carcinoma | October 10, 2018 | October 30, 2023 |
| NCT00154986 | Unknown status | N/A | IGFBP-3 in Ovarian Cancer Invasion | August 2004 | July 2005 |
| NCT05311579 | Unknown status | Phase 2 | Niraparib Plus Anlotinib for Recurrent Ovarian Cancer | March 27, 2022 | March 27, 2024 |
| NCT05310344 | Unknown status | Phase 2 | Albumin-bound Paclitaxel and Bevacizumab for Platinum-resistant Recurrent Ovarian Cancer | March 27, 2022 | March 27, 2024 |
| NCT00715286 | Unknown status | Phase 3 | Neoadjuvant Chemotherapy in Advanced Epithelial Ovarian Cancer (EOC): A Phase III Randomized Study | November 2001 | June 2009 |
| NCT05180851 | Unknown status | Early Phase 1 | Safety and Efficacy of Recombinant Oncolytic Adenovirus L-IFN Injection in Relapsed/Refractory Solid Tumors Clinical Study | November 30, 2021 | December 31, 2023 |
| NCT02083536 | Withdrawn | Phase 1 | LDFWART With Docetaxel in Patients With Platinum-Resistant Recurrent Ovarian Carcinoma | May 2014 | |
| NCT00659399 | Withdrawn | Phase 1 | Feasibility Study of Short Term Fondaparinux (Arixtra) in Chemotherapy-Pretreated Ovarian Carcinoma Patients at High Risk of Progression | January 2008 | November 2010 |
| NCT02878980 | Withdrawn | N/A | An Exercise Intervention Trial to Reduce Symptoms & Improve Clinical Outcomes of Platinum-Based Treatment in Ovarian Cancer Patients | September 2, 2016 | December 2018 |
| NCT04602117 | Withdrawn | Phase 1 | ISPY-P1.01:Evaluating the Safety of Weekly Paclitaxel With Trastuzumab Duocarmazine (SYD985) in Patients With Metastatic Cancer | July 28, 2021 | November 17, 2021 |
| NCT02530606 | Withdrawn | N/A | Photoacoustic Imaging in Detecting Ovarian or Fallopian Tube Cancer | September 2016 | November 2018 |
- Disase is a (Disease Ontology)
- DOID:2151
- Cross Reference ID (Disease Ontology)
- EFO:0001075
- Cross Reference ID (Disease Ontology)
- UMLS_CUI:C0677886
- HPO Human Phenotype ID (Human Phenotype Ontology)
- HP:0025318